BRIEF published on 08/27/2025 at 13:34, 3 months 8 days ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
PRESS RELEASE published on 08/27/2025 at 13:29, 3 months 8 days ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 5 months 8 days ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
PRESS RELEASE published on 06/26/2025 at 10:31, 5 months 8 days ago High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRIEF published on 06/02/2025 at 10:34, 6 months 2 days ago Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
PRESS RELEASE published on 06/02/2025 at 10:29, 6 months 2 days ago Sandra Schröder joins CHEPLAPHARM’S Management Team as VP Scientific Sandra Schröder appointed as VP Scientific at CHEPLAPHARM, responsible for scientific areas globally. Brings 25 years of experience from F. Hoffmann-La Roche AG Pharmaceutical Industry Management CHEPLAPHARM Sandra Schröder VP Scientific
BRIEF published on 01/02/2025 at 09:19, 11 months 2 days ago CHEPLAPHARM Appoints Tamás Szóga as VP Commercial Management Expansion CHEPLAPHARM Tamás Szóga VP Commercial Pharmaceutical Strategy
PRESS RELEASE published on 01/02/2025 at 09:14, 11 months 2 days ago CHEPLAPHARM expands Management with Tamás Szóga as VP Commercial CHEPLAPHARM expands management team by appointing Tamás Szóga as VP Commercial, responsible for strategic planning and development of Global Sales division Global Sales Strategic Planning CHEPLAPHARM Tamás Szóga VP Commercial
BRIEF published on 12/16/2024 at 08:53, 11 months 19 days ago CHEPLAPHARM Acquires Gemzar from Lilly Acquisition Oncology Eli Lilly CHEPLAPHARM Gemzar
PRESS RELEASE published on 12/16/2024 at 08:48, 11 months 19 days ago CHEPLAPHARM acquires Gemzar from Lilly CHEPLAPHARM acquires Gemzar from Lilly, expanding its oncology portfolio with a proven chemotherapeutic agent for various types of cancer Acquisition Oncology CHEPLAPHARM Chemotherapy Gemzar
Published on 12/05/2025 at 02:35, 1 hour 55 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 3 hours 30 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 25 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 30 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 59 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 39 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 4 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 14 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 19 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 10 hours 30 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 45 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 45 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 29 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago Declaration of voting rights at the end of November 2025
